Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata
Key facts
- Who runs it
- Assiut University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 54 people, planned
- Started
- 1 Oct 2024
- Expected to end
- 1 Dec 2027
- Type of study
- Interventional
- Treatments tested
- Simvastatin
- Mometasone Furoate
- Fractional CO2 laser
- Record updated
- 6 May 2024
Who can take part
- Age
- 6 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Patients with patchy alopecia areata involving < 50% of the total scalp
Who cannot take part
- Other causes of hair loss such as; endocrine or immunological disease
- Skin disease in the affected area
- Hypersensitivity or allergy to any of the treatment products used
- Patients with history of hypertrophic scars or keloid formation
- Patients with active infection at the site of the lesion
- Alopecia totalis and alopecia universalis
- Cicatricial alopecia
- Patient using treatment (topical or systemic) for alopecia areata in the last 2 months
- Pregnant and lactating females
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 60 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Alopecia areata (AA) is an autoimmune disorder characterized by non-scarring hair loss of the scalp or any hair-bearing surface.
Read full original descriptionShow less
Alopecia areata affects approximately 2% of the general population. AA has a significant influence on patients' quality of life and may induce psychological disorders.
In AA, CD4+ and CD8+ T-cells violate the immune privilege of the anagen hair follicle, leading to loss of the growing hair shaft. A genome-wide association study demonstrated a genetic predisposition to AA . Additionally, environmental insults, such as viral infections, trauma, or psychosocial stress, have also been suspected to possibly contribute to the development of the disease .
The clinical manifestations of AA vary from small well-defined patches of hair loss to the diffuse involvement of the scalp or the entire body. The majority of AA patients experience unpredictable relapsing and remitting episodes. In a number of patients, it can be persistent, especially when the hair loss is extensive.
Treatments tested
- Simvastatin
- Mometasone Furoate
- Fractional CO2 laser
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata: Clinical, Dermoscopic and Immunohistochemical Study
- Fit questions
- Built from NCT06399783, who can take part
- Record updated
- 6 May 2024